Approval · Notice of Compliance 16644 · 2015
COSENTYX: Notice of Compliance 16644
Issued February 27, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16644
- Date
- February 27, 2015
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Ige-neutralizing antibody (anti-ige)
Products in this notice
Medicinal ingredients
- SECUKINUMAB 150 MG per ML